Loading...
•
Mar 31, 2022
Supernus Q1 2022 Earnings Report
Reported first quarter financial results, highlighted by a 16% increase in total revenues and FDA approval of Qelbree for adults.
Key Takeaways
Supernus Pharmaceuticals reported a strong first quarter in 2022, with a 16% increase in total revenues to $152.5 million compared to Q1 2021. Net earnings and diluted earnings per share (GAAP) were $25.6 million and $0.43, respectively. The FDA approved Qelbree for ADHD treatment in adults, and Qelbree prescriptions increased by 38% compared to Q4 2021.
Total revenues for Q1 2022 reached $152.5 million, a 16% increase year-over-year.
Net earnings for Q1 2022 were $25.6 million, with a diluted EPS of $0.43.
Qelbree prescriptions continued to grow, reaching 47,324 in Q1 2022, a 38% increase compared to Q4 2021.
The FDA approved Qelbree for the treatment of ADHD in adults.
Revenue by Segment
Forward Guidance
Supernus Pharmaceuticals reiterates its full-year 2022 financial guidance, with total revenues expected to be between $640 million and $680 million and operating earnings between $20 million and $40 million.
Positive Outlook
- Total revenues are projected to be between $640 million and $680 million.
- Combined R&D and SG&A expenses are expected to be between $460 million and $490 million.
- Operating earnings are projected to be between $20 million and $40 million.
- Non-GAAP operating earnings are projected to be between $130 million and $165 million.
- Company is preparing for the commercial launch of SPN-830 in the first quarter of 2023, assuming timely approval by the FDA.
Challenges Ahead
- Operating earnings include amortization of intangible assets and contingent consideration expense (gain).
- Decrease in cash and cash equivalents primarily due to milestone payments and transition expense payments.
- Amortization of acquired intangible assets from the Adamas Acquisition.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...